
    
      This is a multi-center, single arm, Phase II clinical trial to investigate the effectiveness
      of acalabrutinib treatment within 6 months of chronic lymphocytic leukemia (CLL) diagnosis
      for patients with CLL deemed at high risk for Richter's Transformation (RT).
    
  